|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
EP2892924B1
(en)
*
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
CN105283201B
(zh)
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
CN105722859B
(zh)
*
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス,インコーポレイティド |
抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
MA41374A
(fr)
*
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
WO2016182064A1
(ja)
*
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
CN114591433A
(zh)
*
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3352760B1
(en)
*
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
US11851488B2
(en)
*
|
2015-11-03 |
2023-12-26 |
Ambrx, Inc. |
Anti-CD3-folate conjugates and their uses
|
|
ES2873846T5
(en)
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
AU2017213886B2
(en)
|
2016-02-04 |
2024-03-07 |
The California Institute For Biomedical Research |
Humanized anti-CD3 antibodies, conjugates and uses thereof
|
|
WO2017143259A1
(en)
*
|
2016-02-19 |
2017-08-24 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CR20180453A
(es)
*
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
|
HRP20230528T1
(hr)
*
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
CN109476741B
(zh)
|
2016-03-25 |
2023-02-24 |
拜奥穆尼克斯制药 |
与cd38和pd-l1结合的分子
|
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス,インク. |
単一ドメイン血清アルブミン結合タンパク質
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
KR102726248B1
(ko)
|
2016-07-07 |
2024-11-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
MX2019004775A
(es)
*
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TWI797097B
(zh)
|
2016-11-28 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
|
WO2018097308A1
(ja)
|
2016-11-28 |
2018-05-31 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
US10610104B2
(en)
|
2016-12-07 |
2020-04-07 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
EP3555620A1
(en)
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
NZ754713A
(en)
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
MA47613A
(fr)
*
|
2017-02-22 |
2020-01-01 |
Aleta Biotherapeutics Inc |
Compositions et procédés de traitement du cancer
|
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
CN120842423A
(zh)
|
2017-03-27 |
2025-10-28 |
拜奥穆尼克斯制药 |
稳定的多特异性抗体
|
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
AU2018250641B2
(en)
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
JP7247110B2
(ja)
*
|
2017-06-05 |
2023-03-28 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
新規抗cd3抗体
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
US11427642B2
(en)
|
2017-06-20 |
2022-08-30 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
EP3645050A4
(en)
*
|
2017-06-25 |
2021-08-11 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
JP2020530554A
(ja)
*
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
CN110799538B
(zh)
*
|
2017-08-28 |
2023-08-01 |
西雅图免疫公司 |
抗cd3抗体及其制备和使用方法
|
|
KR102678252B1
(ko)
*
|
2017-09-01 |
2024-06-26 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
재조합 이중특이적 항체
|
|
IL302613B2
(en)
|
2017-09-08 |
2025-04-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3287794A1
(en)
*
|
2017-10-14 |
2025-10-27 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CN111630062A
(zh)
|
2017-11-28 |
2020-09-04 |
中外制药株式会社 |
具有可调节的配体结合活性的配体结合分子
|
|
CN111836828B
(zh)
|
2017-11-28 |
2024-12-20 |
中外制药株式会社 |
包括抗原结合结构域和运送部分的多肽
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
CN107880129B
(zh)
*
|
2017-12-28 |
2021-01-15 |
广州市鲁诚生物科技有限公司 |
一种重组抗体及其制备方法
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
SG11202007572VA
(en)
*
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
CN110305217B
(zh)
*
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
TW202014436A
(zh)
|
2018-05-02 |
2020-04-16 |
美商Cytomx生物製藥公司 |
抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
US12534734B2
(en)
*
|
2018-05-15 |
2026-01-27 |
Drive Therapeutics Llc |
Stem-loop compositions and methods for inhibiting interleukin-8
|
|
SI3797121T1
(sl)
*
|
2018-05-23 |
2024-09-30 |
Pfizer Inc. |
Protitelesa, specifična za CD3, in njihova uporaba
|
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
US12077577B2
(en)
|
2018-05-30 |
2024-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising aggrecan binding domain and carrying moiety
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
IL279399B1
(en)
*
|
2018-06-14 |
2026-04-01 |
Bioatla Llc |
Multispecific antibody templates
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
MA53333A
(fr)
|
2018-07-31 |
2021-11-03 |
Amgen Inc |
Formulations pharmaceutiques d'anticorps masqués
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3119390A1
(en)
|
2018-11-12 |
2020-05-22 |
Debiopharm International S.A. |
Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
|
|
US20220249814A1
(en)
|
2018-11-19 |
2022-08-11 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
MY205459A
(en)
|
2018-12-06 |
2024-10-22 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
CA3131036A1
(en)
*
|
2019-02-22 |
2020-08-27 |
Wuhan Yzy Biopharma Co., Ltd. |
Cd3 antigen-binding fragment and application thereof
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
JP7776987B2
(ja)
|
2019-04-05 |
2025-11-27 |
テネオバイオ, インコーポレイテッド |
Psmaに結合する重鎖抗体
|
|
EP3966250A4
(en)
*
|
2019-05-07 |
2022-11-23 |
Immunorizon Ltd. |
PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
JPWO2020246563A1
(https=)
|
2019-06-05 |
2020-12-10 |
|
|
|
CN114423499A
(zh)
*
|
2019-06-06 |
2022-04-29 |
佳努克斯治疗公司 |
与肿瘤激活的t细胞衔接子相关的组合物和方法
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
US20230121775A1
(en)
*
|
2019-06-26 |
2023-04-20 |
Amunix Pharmaceuticals, Inc. |
Cd3 antigen binding fragments and compositions comprising same
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Pd-1/cd3二重特異性タンパク質による血液がん治療
|
|
GB201912681D0
(en)
*
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
CN114786776B
(zh)
|
2019-09-18 |
2026-03-24 |
拉姆卡普生物阿尔法股份公司 |
针对ceacam5和cd3的双特异性抗体
|
|
EP4034171A1
(en)
*
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
CN114502203B
(zh)
*
|
2019-11-06 |
2024-07-19 |
成都百利多特生物药业有限责任公司 |
制导和导航控制蛋白及其制备和使用方法
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
CN121197633A
(zh)
|
2019-12-13 |
2025-12-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
EP4090686A4
(en)
*
|
2020-01-17 |
2024-03-27 |
Immune Targeting Inc. |
PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
JP2024518539A
(ja)
*
|
2020-04-04 |
2024-05-01 |
ジャナックス セラピューティクス,インク. |
抗体を標的とする腫瘍によって活性化されるegfrおよびエフェクター細胞抗原に関する組成物および方法
|
|
BR112022019841A2
(pt)
|
2020-04-09 |
2022-12-06 |
Cytomx Therapeutics Inc |
Composições contendo anticorpos ativáveis
|
|
AU2021263448B2
(en)
|
2020-04-29 |
2026-02-05 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
CN116096754A
(zh)
*
|
2020-05-04 |
2023-05-09 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
WO2022035866A1
(en)
|
2020-08-11 |
2022-02-17 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
WO2022046658A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
US12195524B2
(en)
|
2020-08-25 |
2025-01-14 |
Gilead Sciences, Inc. |
Multi-specific antigen binding molecules targeting HIV and methods of use
|
|
US12116411B2
(en)
*
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
KR20230100732A
(ko)
|
2020-11-04 |
2023-07-05 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이성 항체의 피하 투여
|
|
KR20230107305A
(ko)
*
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
|
WO2022115865A2
(en)
*
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
EP4259177A4
(en)
*
|
2020-12-08 |
2024-11-06 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
AU2021396172A1
(en)
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
EP4274617A4
(en)
*
|
2021-01-05 |
2025-04-02 |
Musc Foundation for Research Development |
A BISPECIFIC AGR2XCD3 ENGAGER FOR THE TREATMENT OF CANCER
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR102671734B1
(ko)
*
|
2021-04-13 |
2024-06-04 |
건국대학교 글로컬산학협력단 |
개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
|
|
MX2023012699A
(es)
|
2021-04-30 |
2023-11-21 |
Hoffmann La Roche |
Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
WO2022266341A1
(en)
*
|
2021-06-16 |
2022-12-22 |
Regents Of The University Of Minnesota |
Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
|
|
EP4359443A4
(en)
*
|
2021-06-25 |
2026-02-25 |
Harpoon Therapeutics Inc |
Sustained-release immune cell contact proteins and processing methods
|
|
CN117940459A
(zh)
*
|
2021-08-25 |
2024-04-26 |
西雅图免疫公司 |
靶向egfr和her3的双特异性四价抗体
|
|
WO2023051727A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
上海君实生物医药科技股份有限公司 |
结合cd3的抗体及其用途
|
|
AU2022367525A1
(en)
|
2021-10-15 |
2024-05-02 |
Amgen Inc. |
Activatable polypeptide complex
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
JP2024539650A
(ja)
|
2021-10-15 |
2024-10-29 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化可能なポリペプチド複合体
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
CN118401555A
(zh)
*
|
2021-12-09 |
2024-07-26 |
信华生物药业(广州)有限公司 |
抗体掩蔽物及其用途
|
|
US12269887B2
(en)
|
2022-01-20 |
2025-04-08 |
Regents Of The University Of Minnesota |
Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
|
|
US20250170255A1
(en)
|
2022-02-09 |
2025-05-29 |
Daiichi Sankyo Company, Limited |
Environmentally-responsive masked antibody and use thereof
|
|
WO2023161853A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
CN119110809A
(zh)
|
2022-02-23 |
2024-12-10 |
Xencor股份有限公司 |
抗CD28 x抗PSMA抗体
|
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023183888A1
(en)
|
2022-03-23 |
2023-09-28 |
Cytomx Therapeutics, Inc. |
Activatable antigen-binding protein constructs and uses of the same
|
|
US20250333487A1
(en)
|
2022-03-25 |
2025-10-30 |
Cytomx Therapeutics, Inc. |
Activatable dual-anchored masked molecules and methods of use thereof
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
JP2025511187A
(ja)
|
2022-04-01 |
2025-04-15 |
サイトムエックス セラピューティクス,インク. |
Cd3結合タンパク質及びその使用方法
|
|
CN119013300A
(zh)
|
2022-04-13 |
2024-11-22 |
豪夫迈·罗氏有限公司 |
抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
|
|
US20230406927A1
(en)
*
|
2022-04-29 |
2023-12-21 |
Regents Of The University Of Minnesota |
Masked single-domain antibodies and methods thereof
|
|
JP2025525879A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性基質及びその使用方法
|
|
JP2025525868A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
TW202424183A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Cytomx生物製藥公司 |
蛋白酶可切割受質及其使用方法
|
|
AR130079A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Restos escindibles por proteasas, y métodos de uso de los mismos
|
|
US20260042849A1
(en)
|
2022-08-01 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
GB202214132D0
(en)
*
|
2022-09-27 |
2022-11-09 |
Coding Bio Ltd |
CLL1 binding molecules
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
WO2024102723A2
(en)
*
|
2022-11-10 |
2024-05-16 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
EP4695281A1
(en)
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2024216146A1
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
CN121219014A
(zh)
|
2023-04-17 |
2025-12-26 |
西纳福克斯股份有限公司 |
可切割的免疫细胞接合器
|
|
WO2024243093A2
(en)
*
|
2023-05-19 |
2024-11-28 |
The Regents Of The University Of California |
Multispecific antibodies targeting cd3 and cd22
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
WO2025077737A1
(en)
*
|
2023-10-11 |
2025-04-17 |
Biomap (Suzhou) Intelligent Technology Limited |
An anti-cd3 activable antibody and the use thereof
|
|
WO2025201240A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
|
|
WO2025230233A1
(ko)
*
|
2024-05-03 |
2025-11-06 |
국민대학교산학협력단 |
인간 cd3에 특이적인 항체 및 이의 용도
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|
|
WO2026052652A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026052654A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|